Search

EU Calls for proposal 2021

Introduction
Spurred by COVID-19 and rising challenges to the financial sustainability of Europe’s health systems, a flurry of new EU policies and programs in health has sprung up since last year.

Read more

Jesus San Miguel presents the Ham-Wasserman Lecture at the 2014 ASH Annual Meeting

Professor San Miguel is a member of the Advisory board of the International Myeloma Foundation and the Multiple Myeloma Research Foundation.

Read more

HemaSphere Editorial Board

Editor-in-Chief
Jan Cools, Belgium
Deputy Editor-in-Chief
Claire Harrison, United Kingdom
Associate Editors
Stephen Ansell, USA
Martin Dreyling, Germany
Jeroen Eikenboom, The Netherlands
Adele Fielding, United Kingdom
Paolo Ghia, Italy
Simon Hallam, United Kingdom
Robert Hills, United Kingdom
Steffen Koschmieder, Germany
Martina Mückenthaler, Germany
Paula Rodríguez Otero, Spain
Juerg Schwaller, Switzerland

Francesca Vinchi, USA
Scientific Editors
Charles de Bock,…

Read more

Acute Lymphocytic Leukemia: impressive results with the monoclonal antibody blinatumomab

The Phase 2 dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor Acute Lymphoblastic Leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant.

Read more

How malignant cells in patients with Chronic Lymphocytic Leukemia escape T cell recognition and attack

T cell activation is essential for immunity including the recognition and killing of abnormal target cells such as cancerous cells.

Read more

Reduction of chemotherapy and PET-guided radiotherapy in advanced-stage Hodgkin lymphoma: the GHSG HD15 trial

Using the multi-agent chemotherapy regimen BEACOPP the GHSG demonstrated significantly better tumor control and overall survival compared to previously used regimens. In addition, the need for radiotherapy in patients with advanced stage Hodgkin lymphoma has been unclear.

Read more